Sunday, October 22nd 2023, Madrid,Spain : The results of Phase III trials indicate significant improvements in PFS and OS rates, although the studied population may

The results presented on October 22 2023 at the ESMO Congress 2023 in Madrid, spark a lively debate regarding the use of currently recommended treatment

This paper was presented on October 20 at the ESMO Congress 2023 at Madrid. In the phase 3 EMBARK trial, after a median follow-up of

The final results of the RADICALS-RT trial indicate that observation with salvage radiotherapy for prostate-specific antigen failure should be the standard after surgery. According to

Positive results in advanced or metastatic disease from EV-302/KEYNOTE-A39 and CheckMate 901 indicate for the first time an alternative to first-line chemotherapy. Long-term survival for

There is accumulating evidence that robust political action has the potential to address two of our era’s greatest challenges: climate change and the growing cancer

The results of this study support routine RET mutation testing for all patients with advanced MTC; however, additional research is required to identify predictive markers.

Four early-stage trials demonstrate that combining immune checkpoint inhibitors with other immunotherapies or with TKIs is a potentially effective treatment strategy for a variety of

Sunday, October 22nd 2023, Madrid, Spain : Negative trials presented at the ESMO Congress 2023 suggest that patients with metastatic disease may require a new

Alectinib is the first ALK inhibitor to substantially improve DFS across disease stages in a phase III trial. For patients with completely resected ALKpositive non-small